Showing 6971-6980 of 8179 results for "".
- Kylie Jenner Sells $600 Million Majority Stake in Beauty Business to Cotyhttps://practicaldermatology.com/news/kylie-jenner-sells-600-million-majority-stake-in-beauty-business-to-coty/2460220/Kylie Jenner sold a majority stake in Kylie Cosmetics and Kylie Skin to Coty Inc. Under the terms of the agreement, Coty will acquire a 51 percent ownership in the partnership for $600M. The acquisition is expected to close in the third quarter of fiscal year 2020. Coty's family of
- Celebrate National Botox Day on November 20, 2019https://practicaldermatology.com/news/celebrate-national-botox-day-on-november-20th-2019/2460218/Mark your calendars: November 20, 2019 will be the first-ever National Botox Cosmetic Day. Why Nov. 20? It is the busiest day on record for booking Botox cosmetic treatments in the US. And to commemorate it, Allergan is offering an exclusive deal for one day only where patien
- Psoriasis Onset Determines if Psoriatic Arthritis Patients Develop Arthritis or Psoriasis Firsthttps://practicaldermatology.com/news/psoriasis-onset-determines-if-psoriatic-arthritis-patients-develop-arthritis-or-psoriasis-first/2460212/Age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis., finds a new study presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Additionally, pustular psoriasis is associated with arthritis onset two years earlier than the in
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50
- Going for the Gold: Sebacia Microparticles Help Direct Lasers to the Source of Acnehttps://practicaldermatology.com/news/going-for-the-gold-sebacia-microparticles-help-direct-lasers-to-the-source-of-acne/2460199/Sebacia microparticles may be acne’s latest and greatest nemesis. New research presented the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago shows that the technology helps to safely and effectively clear acne wh
- Galderma Will Begin Seven New Clinical Studieshttps://practicaldermatology.com/news/galderma-will-begin-seven-new-clinical-studies/2460197/Galderma is initiating seven clinical studies that seek to support potential, new aesthetic indications including a tear trough indication for Restylane, a facial wrinkles indication for Sculptra Aesthetic as well as several studies supporting an investigational liquid neurotoxin and a Phase 2 st
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,
- New Indication for Cellfina: Cleared for 5 Years of Benefit for Cellulitehttps://practicaldermatology.com/news/new-indication-for-cellfina-approval-for-5-years-of-benefit-for-cellulite/2460195/The FDA has cleared a new indication statement for Cellfina that shows the benefits of treatment last for five years, an increase from the previous three-year indication. Cellfina from Merz demonstrated five-year improvement in the appearance of cellulite on the buttocks and thighs of adult femal
- FDA Approves Amzeeq Minocycline Foam from Foamixhttps://practicaldermatology.com/news/fda-approves-amzeeq-minocycline-foam-from-foamix/2460194/The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Amzeeq, formerly known as FMX101, is the first topical minoc
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum c